Czech National Bank Grows Stock Holdings in Edwards Lifesciences Corporation $EW

Czech National Bank grew its position in Edwards Lifesciences Corporation (NYSE:EW) by 3.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 163,895 shares of the medical research company’s stock after buying an additional 5,853 shares during the quarter. Czech National Bank’s holdings in Edwards Lifesciences were worth $14,826,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of EW. Norges Bank purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after acquiring an additional 4,108,270 shares in the last quarter. Viking Global Investors LP purchased a new stake in Edwards Lifesciences during the third quarter worth about $238,688,000. Marshall Wace LLP increased its stake in Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Edwards Lifesciences by 132.4% during the first quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock worth $310,984,000 after purchasing an additional 2,212,208 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.4%

EW opened at $89.65 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $51.62 billion, a price-to-earnings ratio of 51.52, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The business’s 50 day moving average is $88.19 and its two-hundred day moving average is $84.08.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the business earned $0.67 earnings per share. The business’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on EW. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Barclays reaffirmed an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Mizuho increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Piper Sandler reissued an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, Evercore restated an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 43,539 shares of company stock worth $3,685,364. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.